Stepan (SCL) Q2 2025 Earnings Call Transcript

Stepan reported second-quarter adjusted EBITDA of $51.4 million, up 8%, and adjusted net income of $12 million, up 27%, helped by Polymers strength and a lower effective tax rate. Results were tempered by a $14.4 million negative free cash flow, higher oleochemical raw material costs, Pasadena start-up expenses, and Millsdale remediation and labor-related cash outflows. Management said Pasadena is still ramping, full contribution is expected in Q4 2025, and the quarterly dividend was raised to $0.385 per share.

Analysis

This is not a clean earnings beat; it is a margin-repair story with a temporary tax tailwind and a working-capital drag. The key second-order dynamic is that the company is front-loading inventory and start-up costs now to buy optionality against tariffs, hurricanes, and Pasadena ramp, which should make the next two quarters look mechanically better if demand merely stays stable. That sets up a potential “bad cash flow, better optics” rebound trade, but only if raw materials stop outrunning price resets.

The Surfactants issue is more important than the headline suggests: if input inflation persists, competitors with less exposure to coconut-oil-linked feedstocks or better formula flexibility can take share on price stability, especially in consumer end markets where customers are already trading down. Management’s commentary implies pricing lag, not structural demand destruction, so the earnings power debate is really about how fast contract repricing can close the gap; that favors a sharper margin inflection in 3Q/4Q than the market may be modeling. Pasadena and AOS capacity are the strategic offsets, but they matter most in 2026, not the next few weeks.

The setup is mildly constructive for the stock only if investors anchor to normalized tax and cash flow rather than quarter-to-quarter noise. The contrarian risk is that the market underestimates how long elevated inventory and remediation/one-time costs suppress reported free cash flow, which can keep a quality dividend compounder in a valuation box despite improving operating trends. Conversely, if the tax rate normalizes and the June pricing actions flow through by late 3Q, consensus EPS revisions could grind higher without needing a demand recovery.

Key Decisions for Investors

• Long SCL on a 3-6 month horizon as a cash-flow normalization trade, but size modestly: the setup is attractive only if raw-material inflation stabilizes and Pasadena ramp begins to contribute; upside comes from margin catch-up and tax-rate normalization, while downside is limited by dividend support.
• Buy SCL Jan-2026 call spreads financed with a partial put sale if liquidity allows; the thesis is that reported FCF and EBITDA improve into 4Q/1Q as inventory builds reverse, but the premium paid should be limited because the near-term quarter can still look noisy.
• Pair long SCL vs short a higher-multiple specialty chemical peer with greater feedstock exposure if you can source a clean comp; the relative trade benefits from SCL’s visible end-market diversification and 2026 Pasadena optionality while keeping commodity inflation beta neutral.
• Do not chase the stock immediately on the call print; wait for either a 3Q margin update or evidence that pricing is catching raw-material inflation. The best entry is likely on any selloff tied to weak near-term cash flow optics.
• Watch for a tactical add if management confirms free cash flow turns positive in the next update; that would validate the inventory build as temporary and likely force estimate revisions higher over the following 1-2 quarters.